Table 3.
Results of laboratory tests.
| Variables | Intervention (n = 14) | Control (Placebo) (n = 9) | ||
|---|---|---|---|---|
| Baseline Mean ± SD |
Final Mean ± SD |
Baseline Mean ± SD |
Final Mean ± SD |
|
| Total cholesterol, mg/dL | 236 ± 27 | 228 ± 26 * | 246 ± 48 | 241 ± 42 |
| Triglycerides, mg/dL | 124 ± 48 | 108 ± 92 | 117 ± 46 | 122 ± 102 |
| LDL-C, mg/dL | 159 ± 21 | 151 ± 17 | 168 ± 31 | 170 ± 24 |
| HDL-C, mg/dL | 56.5 ± 16.4 | 57.8 ± 15.6 | 57.6 ± 16.0 | 56.8 ± 15.3 |
| HDL-C/LDL-C ratio † | 0.36 ± 0.10 | 0.38 ± 0.10 * | 0.36 ± 0.14 | 0.34 ± 0.11 |
| ox-LDL, U/L † | 93.8 ± 19.1 | 62.8 ± 28.7 * | 98.2 ± 23.5 | 105.7 ± 21.9 |
| ox-LDL/LDL-C ratio † | 0.60 ± 0.16 | 0.43 ± 0.22 * | 0.59 ± 0.11 | 0.64 ± 0.19 |
| Apolipoprotein A1, mg/dL | 127.4 ± 25.0 | 134.2 ± 26.5 | 126.8 ± 47.9 | 122.9 ± 37.7 |
| Apolipoprotein B, mg/dL | 110.8 ± 13.2 | 105.6 ± 10.2 | 123.2 ± 35.4 | 114.7 ± 28.2 |
| Paraoxonase, U/L | 64.5 ± 15.6 | 78.7 ± 28.8 * | 81.6 ± 26.3 | 80.4 ± 27.4 |
| Hemoglobin, g/dL | 14.9 ± 1.4 | 14.3 ± 1.1 | 14.6 ± 1.0 | 14.3 ± 1.0 |
| Leukocyte count, × 109/L | 6.1 ± 1.5 | 5.9 ± 1.6 | 6.9 ± 1.5 | 7.0 ± 1.2 |
| Creatinine, mg/dL | 0.9 ± 0.2 | 1.0 ± 0.2 | 0.9 ± 0.2 | 1.0 ± 0.2 |
| ALT, U/L | 28.7 ± 17.9 | 20.2 ± 7.6 | 33.8 ± 16.7 | 45.1 ± 47.4 |
| AST, U/L | 21.9 ± 5.2 | 18.8 ± 6.8 | 25.5 ± 7.2 | 30.6 ± 22.0 |
| GGT, U/L | 41.5 ± 46.3 | 31.4 ± 23.3 | 34.8 ± 22.7 | 46.4 ± 40.3 |
LDL-C: low-density lipoprotein cholesterol; HDL-C: high-density lipoprotein cholesterol; ox-LDL: oxidized LDL; ALT: alanine aminotransferase; AST: aspartate aminotransferase; GGT: gamma-glutamyl transpeptidase. * Indicates statistically significant differences between baseline and end of the study (p < 0.05); † Indicates statistically significant differences when comparing the evolution between groups (p < 0.05).